AUTHORS
Jing Voon Chen, PhD, Emily L. Waters, PhD2, Graceanne R. Wayser, MPH3, Nicole Bariahtaris, BA4, Claire Cagle, MPH5, Melissa Culhane Maravic, PhD, MPH6, Robert F. Sidonio Jr, MD,MSc7
AFFILIATIONS
1 Novo Nordisk Inc., Plainsboro, New Jersey, United States
2 Novo Nordisk Inc., Plainsboro, New Jersey, United States
3 Precision AQ, New York, New York, United States
4 Precision AQ, New York, New York, United States
5 Precision AQ, New York, New York, United States
6 Precision AQ, New York, New York, United States
7 Emory University Hospital, Atlanta, Georgia, United States, HOG Pediatric Center for Bleeding and Clotting Disorders, Atlanta, Georgia, United States
ABSTRACT
Introduction
In the last decade, the treatment landscape for hemophilia A (HA) has expanded to include long-acting factor replacement therapy and nonfactor therapies (NFTs), offering patients more prophylactic options with different routes of administration and dosing frequencies. However, little is known about how patients and health care professionals (HCPs) evaluate factor therapies and NFTs, and the drivers and barriers that influence treatment switching. This study explored patient and HCP perspectives on treatment selection and switching to identify opportunities to support and facilitate shared decision-making.
Methods
This qualitative study consisted of 60-minute, web-based, semi-structured interviews conducted from January to May 2026 among patients with HA and HCPs practicing at hemophilia treatment centers. Patients included adults, adolescents, and caregivers (patient proxies) for children aged <13 years (hereafter referred to as “patients”). Interviews explored treatment experiences, unmet needs, treatment preferences, and the drivers, barriers, and facilitators to selecting and switching between factor therapies and NFTs. Interviews were audio-recorded, transcribed, and qualitatively analyzed using NVivo to synthesize findings across key topics.
Results
Among the 11 patients with HA, efficacy was the key driver of treatment selection, whereas safety and reduced treatment burden were secondary. Safety emerged as the key driver of treatment recommendations among the 20 HCPs, followed by efficacy, adherence, and real-world practicality. HCPs favored weekly or biweekly dosing frequencies to balance bleed protection with adherence and patient lifestyle. Patients preferred biweekly/monthly/bimonthly dosing intervals (biweekly considered optimal), and treatments that were compatible with their lifestyle and physical activity level, had minimal storage requirements, and were easily accessible, particularly in rural or resource-limited environments. HCPs reported tailoring treatment recommendations for patient life stages, often favoring NFTs during adolescence and young adulthood as responsibility shifts from caregiver to patient; conversely, strong caregiver involvement sometimes enabled continued factor use. For patients who were clinically stable and satisfied with factor therapy, HCPs viewed switching as elective rather than clinically necessary and prioritized minimizing disruption to established routines. Patients who chose to remain on factor therapy expressed satisfaction and trust in a long-established treatment with proven efficacy and reliable bleed control. Patients reported that uncertainty of how to monitor effectiveness, limited real-world data, perceived risks, and access and administrative challenges are key barriers to the adoption of NFTs. Real-world drivers of treatment switching most often included the negative impact of factor therapy on daily life, worsening symptoms, greater convenience associated with NFTs, and trusted clinical guidance or peer validation.
Overall, patients expressed less awareness of newer NFTs, with some reporting becoming aware of these treatments through engagement with manufacturers, HCPs, and the hemophilia community. Greater familiarity with emerging therapies was reported by patients who engaged in community activities or educational events. However, when patients reported satisfaction with their treatment, some patients and HCPs indicated not engaging in discussions about new treatment options. Patients often requested real-world evidence from other patients with similar disease characteristics, ages, and physical activity levels to feel comfortable switching treatments.
Conclusion
Patients and HCPs differed in their perceptions of optimal dosing frequency, with patients preferring longer dosing intervals compared to HCPs. Adoption of NFTs may depend not only on clinical suitability but also on lifestyle compatibility, trusted real-world evidence, and patient success stories. During treatment discussions, HCPs should provide patients with information on side effects, personalized data tailored to their age, activity level, and disease characteristics, and guidance on treatment monitoring, bleed management, costs, and insurance coverage. Greater patient awareness of available treatment options and education may support shared decision-making and guide appropriate treatment selection.
DISCLOSURES
Jing Voon Chen, PhD: Novo Nordisk Inc. - Current Employment